![](/img/cover-not-exists.png)
PDB54 COMPARISON OF TREATMENT COSTS BETWEEN BASAL-SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE (GLA) AND BOT WITH INSULIN DETEMIR (DET) IN PATIENTS WITH TYPE 2 DIABETES (T2D): ECONOMIC EVALUATION BASED ON THE RESULTS OF THE INSULIN GLARGINE (LANTUS®) VERSUS INSULIN DETEMIR (LEVEMIR®) TREAT-TO-TARGET (L2T3) STUDY
PK Schädlich, KC Koltermann, FW Dippel, EG Hagenmeyer, B HäusslerVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)72112-x
File:
PDF, 81 KB
english, 2010